Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXISSTU:135 40 Buyback Yield % is -77.65 as of Aug. 16, 2026. GuruFocus rates STU:135 with a GF Score™ of 40/100 and a GF Value™ of €16.22. The stock has 3 warning signs investors should review. Among 268 Drug Manufacturers companies, SCYNEXIS ranks worse than 95.9% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for SCYNEXIS's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:135 vs IXHL, ETST, INIS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (STU:135) has a Buyback Yield % of -77.65 as of Aug. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on SCYNEXIS and its competitors. According to the industry distribution chart, SCYNEXIS ranks #257 out of 268 companies in the Drug Manufacturers industry, placing it in the top 95.9%.
Is SCYNEXIS's Buyback Yield % too high?
SCYNEXIS's current Buyback Yield % is -77.65. Based on the distribution chart, SCYNEXIS ranks #257 out of 268 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Buyback Yield % compare to IXHL and ETST?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #257 out of 268 companies for Buyback Yield %. This places SCYNEXIS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Buyback Yield % is -77.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (STU:135) has a current Buyback Yield % of -77.65. The stock's GF Value™ is €16.22, compared to a current price of €4.84 — trading 70.2% below its estimated fair value. The current Buyback Yield % is -77.65. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Buyback Yield % is -77.65 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (STU:135) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of €4.84 is trading 70.2% below its estimated GF Value™ of €16.22.
Key valuation signals for STU:135:
Buyback Yield %: -77.65
GF Value™: €16.22 vs. price of €4.84 (70.2% below fair value)
No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score
Get the complete analysis for STU:135
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:135 has been successfully added to your 
